Should FDA cut out the time-consuming legal review of draft warning letters in order to expedite their delivery to pharma companies?
Yes
75%
No
25%
Newsletters
Behind-the-headlines pharmaceutical global sales + marketing news and analysis every other Wednesday, helping you break down breaking news from an industry perspective.
Giving you the features on new campaigns, agency-client relationships, and personnel changes, and drug marketing news on account wins, case studies and trends every other Wednesday.
